LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Blueprint Medicines Corp

Închisă

SectorSănătate

127.83 -0.02

Rezumat

Modificarea prețului

24h

Curent

Minim

127.51

Maxim

128.01

Indicatori cheie

By Trading Economics

Venit

50M

496K

Vânzări

3M

149M

EPS

-0.294

Marjă de profit

0.332

Angajați

682

EBITDA

-14M

-41M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+1.35% upside

Dividende

By Dow Jones

Următoarele câștiguri

31 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

2.5B

8.3B

Deschiderea anterioară

127.85

Închiderea anterioară

127.83

Sentimentul știrilor

By Acuity

32%

68%

87 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Blueprint Medicines Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 iun. 2025, 09:17 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 iun. 2025, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

2 iun. 2025, 13:50 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 iun. 2025, 10:50 UTC

Achiziții, Fuziuni, Preluări

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 iun. 2025, 10:05 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 iun. 2025, 05:06 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 iun. 2025, 05:06 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 iun. 2025, 05:05 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 iun. 2025, 05:05 UTC

Achiziții, Fuziuni, Preluări

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 iun. 2025, 05:04 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 iun. 2025, 05:04 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 iun. 2025, 05:03 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Blueprint Medicines Corporation

2 iun. 2025, 05:02 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Acquire Blueprint Medicines Corporation

Comparație

Modificare preț

Blueprint Medicines Corp Așteptări

Obiectiv de preț

By TipRanks

1.35% sus

Prognoză pe 12 luni

Medie 129.63 USD  1.35%

Maxim 143 USD

Minim 105 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBlueprint Medicines Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

20 ratings

4

Cumpărare

16

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

87.66 / 99.25Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

87 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.